Y-mAbs Therapeutics, Inc
Y-mAbs Therapeutics is dedicated to developing and commercializing innovative radioimmunotherapy and antibody-based therapies to treat challenging diseases, with a focus on pediatric oncology and expanding access to novel cancer treatments. Founded in 2015 by Thomas Gad, the company aims to improve and extend patients' lives through scientific innovation and strategic partnerships.
Industries
Nr. of Employees
medium (51-250)
Y-mAbs Therapeutics, Inc
Products
Danyelza (naxitamab-gqgk) 40 mg/10 mL injection
Commercial antibody-based therapeutic product with prescribing information and boxed warnings; prescribing details and full labeling are provided via the product's prescribing information link.
Danyelza (naxitamab-gqgk) 40 mg/10 mL injection
Commercial antibody-based therapeutic product with prescribing information and boxed warnings; prescribing details and full labeling are provided via the product's prescribing information link.
Services
Patient access and support programs
Insurance navigation, access assistance and financial support services for eligible patients delivered via a dedicated patient support program.
Medical information provision
Medical information responses for healthcare professionals via phone, email and a dedicated medical website.
Pharmacovigilance and adverse event reporting
Channels and processes for reporting adverse reactions, product complaints and coordination with regulatory reporting systems.
Partnerships and co-development
Business development and collaboration services for global expansion, co-development of therapeutic candidates and platform licensing.
ISS grant submission portal
Submission portal for ISS grant proposals.
Patient access and support programs
Insurance navigation, access assistance and financial support services for eligible patients delivered via a dedicated patient support program.
Medical information provision
Medical information responses for healthcare professionals via phone, email and a dedicated medical website.
Pharmacovigilance and adverse event reporting
Channels and processes for reporting adverse reactions, product complaints and coordination with regulatory reporting systems.
Partnerships and co-development
Business development and collaboration services for global expansion, co-development of therapeutic candidates and platform licensing.
ISS grant submission portal
Submission portal for ISS grant proposals.
Expertise Areas
- Antibody therapeutics
- Radiopharmaceuticals and radioimmunotherapy
- Preclinical development and IND-enabling studies
- Clinical trial management and execution
Key Technologies
- Antibody-based therapeutics
- Pretargeted radioimmunotherapy platforms
- Radiopharmaceutical delivery
- In vitro biochemical and cell-based assays